Bevacizumab improves efficacy, including 1-year OS rates, both overall and in subgroups of poor-prognosis patients with limited treatment options.

No abstract

Limited data are available regarding treatment patterns, healthcare resource utilization (HCRU), treatment costs and clinical outcomes for patients with diffuse large B-cell lymphoma (DLBCL) in Japan. This retrospective database study analyzed the Medical Data Vision database for DLBCL patients who received treatment during the identification period from October 1 2008 to December 31 2017. Among 6,965 eligible DLBCL patients, 5,541 patients (79.6%) received first-line (1L) rituximab (R)-based therapy, and then were gradually switched to chemotherapy without R in subsequent lines of therapy. In each treatment regimen, 1L treatment cost was the highest among all lines of therapy. The major cost drivers i.e. total direct medical costs until death or censoring across all regimens and lines of therapy were from the 1L regimen and inpatient costs. During the follow-up period, DLBCL patients who received a 1L R-CHOP regimen achieved the highest survival rate and longest time-to-next-treatment, with a relatively low mean treatment cost due to lower inpatient healthcare resource utilization and fewer lines of therapy compared to other 1L regimens. Our retrospective analysis of clinical practices in Japanese DLBCL patients demonstrated that 1L treatment and inpatient costs were major cost contributors and that the use of 1L R-CHOP was associated with better clinical outcomes at a relatively low mean treatment cost.

Aim: This observational study evaluated the effectiveness of nab-paclitaxel versus paclitaxel monotherapy as first-line (1L) treatment for metastatic triple-negative breast cancer (mTNBC). Materials & methods: 200 patients from the US Flatiron Health electronic health record-derived database (mTNBC diagnosis, January 2011–October 2016) who received 1L nab-paclitaxel (n = 105) or paclitaxel (n = 95) monotherapy were included. Overall survival and time to next treatment were evaluated. Results: The adjusted overall survival hazard ratio was 0.98 (95% CI: 0.67–1.44), indicating a similar risk of death between groups. Adjusted time to next treatment hazard ratio was 0.89 (95% confidence interval: 0.62–1.29). Conclusion: Nab-paclitaxel and paclitaxel monotherapy showed similar efficacy, suggesting their interchangeability as 1L treatments for mTNBC.

is a chronic inflammatory skin disease in which approximately 90% of patients are characterized by well-demarcated and erythematous plaques covered with silvery scales. 1 The prevalence of PsO ranges from 0.09% to 11.4% worldwide, with an estimated 100 million people affected. 2,3 A claims database study using data from 2010 to 2011 reported that more than 400 000 people are living with PsO in Japan, with a prevalence estimated to be 0.34%. 4 The physical, economic, and psychological burdens of PsO are substantial. 5 This disease negatively affects social functioning, including decreased work efficiency and distress at work due to skin symptoms such itching or redness. 6 Occupational impairment leads to lower wages or barriers to promotion, further exacerbating the psychosocial burden of PsO. 7 Additionally, a large proportion of patients experience

differentially methylated in LG and HG BC using two different genomewide methylation-profiling platforms. Multivariable logistic regression prediction models were created.RESULTS: There were 211 bladder cancer patients (180 nonmuscle invasive) and 102 controls. In univariate analyses, all methylation biomarkers were statistically significant predictors of cancer vs. no cancer (all p-values <0.01), and HG vs. LG-BC (all p-values<0.01). In multivariable analysis, NID2, TWIST1 and age were independent predictors of BC (all p<0.05). Multivariable models predicting BC overall and discriminating between high-grade and lowgrade bladder cancer reached AUCs of 0.89 and 0.78, respectively.CONCLUSIONS: Our multi-centric study supports the promise of epigenetic urinary markers in non-invasively detecting bladder cancer and discriminating between grades. Validation in different clinical settings including patients with hematuria, bladder cancer surveillance or screening in high-risk populations is warranted to support its utility.

No abstract

Introduction Adult T‐cell leukemia‐lymphoma (ATL) is a mature T‐cell lymphoproliferative neoplasm caused by human T‐cell leukemia virus type‐1 infection. There is no standard treatment for relapsed or refractory (r/r) ATL, and clinical outcomes are poor. This systematic review examined the survival outcomes for r/r ATL treated with various systemic therapies. Methods EMBASE and PubMed were searched for studies on r/r ATL, published between January 2010 and January 2020. The main outcome of interest was overall survival (OS). Median OS and an exploratory 30% OS time were assessed based on published data and Kaplan‐Meier curves. Results There were 21 unique treatment subgroups (from 14 studies), that met the eligibility criteria. Nine subgroups were mogamulizumab treatment, two were mogamulizumab prior to allogenic hematopoietic stem cell transplantation (allo‐HSCT), five were allo‐HSCT, and five were other chemotherapy. Respectively, the median OS and 30% OS varied considerably in range for mogamulizumab treatment (2.2–17.6 months and 8.7–27.1 months), allo‐HSCT (3.8–6.2 months and 7.5–19.8 months), and other chemotherapy arms (4.1–20.3 months and 7.1–17.0 months). Conclusion Mogamulizumab was the most frequently studied treatment regimen and can potentially provide longer survival compared with chemotherapy alone. Future comparisons with synthetic or historical control arms may enable clearer insights into treatment efficacy.